The effect of omega-3 on the side effects of tamoxifen in women with breast cancer

The effect of omega- 3 on quality of life,menopausal sumptoms and sextual dysfunction in tamoxifen consumer women with breast cancer that refer to motahhari breast cancer clinic in 1390

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201104052515N3

Enrollment

140

Registered

2012-08-09

Start date

2011-11-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Quqlity of life, side effect of menopauses,sexual dysfunction. -

Interventions

Intervention 1: omega-3 1000 mg capsule one times a day for three months. Intervention 2: omega-3 1000 mg capsule one time a day for three months.

Prevention

Placebo

omega-3 1000 mg capsule one times a day for three months

omega-3 1000 mg capsule one time a day for three months

Eligibility

Sex/Gender

Female

Age

No minimum to 50 Years

Inclusion criteria

Inclusion criteria: Medical record review identified female patients who were initially diagnosed as stage 1 and 2 with breast cancer prior to menopause age or menopause are not related to medication or surgery, married, be literate, signed and confirmed consent form, completed adjuvant treatment such as chemotherapy, hormonal therapy with tamoxifen or suffered by tamoxifen treatment side effects such as; hot flashes, sexual dysfunction, night sweats, negative impact on life quality, that met the inclusion criteria. After deletion of patients who met specific exclusion criteria such as; high blood pressure, blood lipids, renal and thyroid dysfunction, history of allergy to O-3, using medication or food complementary for the purpose of preventing or reducing complications and/or side effects of tamoxifen treatment, using medication to treat mental disorder, having sever and progressive disease(s), disease relapsation, those patients who were initially or latelly diagnosed with advanced stages (>2) of breast cancer and finally those one unwillingness to continue participation in research.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hot flashes. Timepoint: befor intervention and three months after intervention. Method of measurement: part of the grin questionnaire.;Night sweats. Timepoint: before intervention and Three months after intervention. Method of measurement: part of the grin questionnaire.;Quality of life. Timepoint: befor intervention and three months after intervention. Method of measurement: QLQ-C30 questionnaire.;Sexual dysfunction. Timepoint: before intervention and three months after intervention. Method of measurement: FSFI questionnaire.	—

Measure

Time frame

Hot flashes. Timepoint: befor intervention and three months after intervention. Method of measurement: part of the grin questionnaire.;Night sweats. Timepoint: before intervention and Three months after intervention. Method of measurement: part of the grin questionnaire.;Quality of life. Timepoint: befor intervention and three months after intervention. Method of measurement: QLQ-C30 questionnaire.;Sexual dysfunction. Timepoint: before intervention and three months after intervention. Method of measurement: FSFI questionnaire.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026